Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$257K Sell
10,679
-5,336
-33% -$140K 0.08% 137
2026
Q1
$434K Buy
16,015
+11
+0.1% +$293 0.15% 91
2025
Q4
$403K Sell
16,004
-794
-5% -$20K 0.14% 103
2025
Q3
$457K Sell
16,798
-86
-0.5% -$2.12K 0.17% 84
2025
Q2
$423K Sell
16,884
-1,209
-7% -$28.2K 0.17% 89
2025
Q1
$409K Sell
18,093
-465
-3% -$12.2K 0.19% 75
2024
Q4
$488K Sell
18,558
-2,104
-10% -$57.1K 0.21% 70
2024
Q3
$591K Buy
20,662
+457
+2% +$13.3K 0.28% 61
2024
Q2
$560K Sell
20,205
-404
-2% -$11.1K 0.28% 62
2024
Q1
$542K Sell
20,609
-771
-4% -$21.4K 0.3% 65
2023
Q4
$630K Sell
21,380
-1,019
-5% -$30.8K 0.42% 47
2023
Q3
$760K Sell
22,399
-4,047
-15% -$143K 0.58% 36
2023
Q2
$954K Sell
26,446
-4,190
-14% -$163K 0.67% 27
2023
Q1
$1.27M Sell
30,636
-365
-1% -$15.8K 0.95% 14
2022
Q4
$1.47M Sell
31,001
-180
-0.6% -$8.63K 1.11% 10
2022
Q3
$1.36M Buy
31,181
+391
+1% +$19K 1.19% 9
2022
Q2
$1.63M Buy
30,790
+1,108
+4% +$56.5K 1.27% 9
2022
Q1
$1.44M Buy
29,682
+3,824
+15% +$198K 1.09% 11
2021
Q4
$1.37M Buy
+25,858
New +$1.28M 1.07% 12

Other funds holding PFE

MKT Advisors's PFE Position: Q2 2026 in Review

MKT Advisors reduced its Pfizer (PFE) stake by 33% in Q2 2026, selling an estimated $140K and leaving 10,679 shares worth $257K. The position accounts for 0.08% of the portfolio, ranked #137.

MKT Advisors first reported a position in PFE in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.63M in Q2 2022. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • MKT Advisors held 10,679 shares of Pfizer worth $257K as of Q2 2026.
  • MKT Advisors sold 5,336 Pfizer shares in Q2 2026, an estimated $140K.
  • Pfizer made up 0.08% of MKT Advisors's portfolio in Q2 2026, its #137 holding.
  • MKT Advisors first reported a position in Pfizer in Q4 2021 and has held it in 19 quarters since.
  • MKT Advisors's Pfizer position peaked at $1.63M in Q2 2022.
  • 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on MKT Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.